Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastroesophageal junction cancer
NL-OMON39981Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pertuzumab combination arm with Placebo control arm (2 arms). Primary endpoint: Overall survival. Started Mar 2014; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON39981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39981.